Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

259517 items
10:08 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Tetraphase launches Xerava in the U.S.

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) launched Xerava eravacycline in the U.S. to treat complicated intra-abdominal infections (cIAIs) in adults at a wholesale acquisition cost (WAC) of $175 per day. According to its U.S. label, Xerava is...
10:06 AM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Velicept raises additional $15M in series B

Velicept Therapeutics Inc. (Malvern, Pa.) raised $15 million in a series B round extension led by Samsara BioCapital. Existing investors CDK, Fountain Healthcare, Longitude Venture Partners and Becker Ventures also participated. Becker Ventures is Velicept's...
10:05 AM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Verastem raises $150M in notes offering

Verastem Inc. (NASDAQ:VSTM) raised $150 million on Oct. 11 through the sale of 5% convertible senior notes due 2048. The notes have an initial conversion price of about $7.16, which is a 14% premium to...
9:52 AM, Oct 19, 2018  |  BC Extra | Preclinical News

Study uncovers large batch effects in TCGA exome sequencing data

A preprint article published in bioRxiv identified large cross-institutional batch effects for a subset of The Cancer Genome Atlas data. The report provides a warning to all multisite sequencing consortia, and calls for re-examining results...
5:26 AM, Oct 19, 2018  |  BC Extra | Financial News

Ahead of Phase II, TP raises $80M mezzanine round

Oncology company TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round and promoted Athena Countouriotis to CEO from CMO as the company readies to begin a potentially registrational Phase II study...
5:55 PM, Oct 18, 2018  |  BC Innovations | Translation in Brief

Sorting out exosomes

A team of Japanese researchers have identified UBL3 as a new therapeutic target for cancers and neurodegenerative diseases that spread via the exosome-based intercellular communication system. The ubiquitin system sorts proteins for cellular export via...
5:40 PM, Oct 18, 2018  |  BC Innovations | Emerging Company Profile

Altheia: Proliferating PD-L1

Rather than blocking PD-L1 to treat cancer, Altheia Science s.r.l. is increasing expression of PD-L1 via a cell therapy to promote immune tolerance in autoimmune diseases, starting with Type I diabetes and multiple sclerosis. Altheia...
5:36 PM, Oct 18, 2018  |  BC Innovations | Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
4:44 PM, Oct 18, 2018  |  BC Innovations | Targets & Mechanisms

Volkow: why pain and addiction will go personalized

While addiction still carries a social stigma, neuroscience research not only supports the view that it is a disease, but is starting to paint a more nuanced picture of the variety of mechanistic pathways involved....
3:37 PM, Oct 18, 2018  |  BC Extra | Politics & Policy

CMS’s Verma outlines new drug payment options

CMS Administrator Seema Verma Thursday outlined three types of payment arrangements the agency is considering for new, expensive medicines, such as gene therapies. Speaking at the Brookings Institution, Verma said CMS may modify its regulations...